Tech Company Financing Transactions
Virdante Pharmaceuticals Funding Round
Virdante Pharmaceuticals, operating out of Cambridge, received $1.3 million from Venrock.
Transaction Overview
Company Name
Announced On
6/30/2009
Transaction Type
Venture Equity
Amount
$1,250,000
Round
Undisclosed
Investors
Venrock (Anders Hove)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
14 Cambridge Center Bldg 1
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Virdante is a privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Pat Gage
Chief Executive Officer
John Ripple
Browse more venture capital transactions:
Prev: 6/30/2009: Certeon venture capital transaction
Next: 6/30/2009: ApniCure venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs